Loading
A phase 2 trial of Nivolumab, Ipilimumab, Carboplatin in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06946797 by Bristol-Myers Squibb, with 76 participants planned, started 2025-09-19 and due to reach its primary completion in 2027-02-05. Interventions recorded: Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Bristol Myers Squibb, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/